Exelixis Inc (EXEL)
23.71
+0.42
(+1.80%)
USD |
NASDAQ |
Apr 24, 16:00
23.70
0.00 (0.00%)
After-Hours: 20:00
Exelixis Revenue (Annual): 1.830B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.830B |
| December 31, 2022 | 1.611B |
| December 31, 2021 | 1.435B |
| December 31, 2020 | 987.54M |
| December 31, 2019 | 967.78M |
| December 31, 2018 | 853.83M |
| December 31, 2017 | 452.48M |
| December 31, 2016 | 191.45M |
| December 31, 2015 | 37.17M |
| December 31, 2014 | 25.11M |
| December 31, 2013 | 31.34M |
| December 31, 2012 | 47.45M |
| December 31, 2011 | 289.64M |
| Date | Value |
|---|---|
| December 31, 2010 | 185.04M |
| December 31, 2009 | 151.76M |
| December 31, 2008 | 117.86M |
| December 31, 2007 | 113.47M |
| December 31, 2006 | 98.67M |
| December 31, 2005 | 75.96M |
| December 31, 2004 | 52.86M |
| December 31, 2003 | 51.54M |
| December 31, 2002 | 44.32M |
| December 31, 2001 | 41.01M |
| December 31, 2000 | 24.76M |
| December 31, 1999 | 10.50M |
| December 31, 1998 | 2.272M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
967.78M
Minimum
2019
1.830B
Maximum
2023
1.366B
Average
1.435B
Median
2021
Revenue (Annual) Benchmarks
| Regeneron Pharmaceuticals Inc | 13.12B |
| Bristol-Myers Squibb Co | 45.01B |
| Johnson & Johnson | 85.16B |
| Bio-Techne Corp | 1.137B |
| Legend Biotech Corp | 285.14M |